Gilead
Gilead gets CHMP nod
November 25, 2013Research and Development, Sales and Marketing CHMP, FDA, Gilead, chc, sovaldi
The CHMP has opened the way for Gilead Sciences’ first-in-class investigational chronic hepatitis C drug Sovaldi (sofosbuvir) to get to …
‘Game-changing’ hep C pill gets FDA panel nod
October 29, 2013Sales and Marketing FDA, Gilead, hep C, sofosbuvir
Gilead Science’s investigational hepatitis C drug sofosbuvir is one step closer to approval in the US after an FDA advisory …
New HIV pill for UK
May 29, 2013Sales and Marketing Gilead, HIV, stribild
Gilead Sciences has launched Stribild, a once-daily single tablet regimen to combat HIV – the virus which causes AIDS – …
Manufacturing issues block Gilead approvals
May 1, 2013Manufacturing and Production FDA, Gilead
The FDA has blocked approval of two of Gilead Sciences’ HIV drugs because of deficiencies in their marketing applications related …
Gilead recalls Vistide on particle contamination
February 19, 2013Manufacturing and Production Gilead, Vistide
Gilead Sciences has issued a voluntary recall of one lot of its antiviral treatment Vistide after finding particulate matter in …
Gilead licences MacroGenics technology
January 9, 2013Research and Development, Sales and Marketing DART, Gilead, MacroGenics
Private biotech company MacroGenics has licenced its bi-specific antibody platform technology to Gilead Sciences for products aimed at four unnamed …
Merck enters €110m virus alliance
October 16, 2012Research and Development, Sales and Marketing AiCuris, Gilead, HCMV, Merck
Merck has gained access to AiCuris’ portfolio of investigational medicines targeting human cytomegalovirus (HCMV) via a global licensing agreement. It …
New quad HIV pill passed by FDA
September 2, 2012Sales and Marketing FDA, Gilead, HIV, stribild
Gilead’s four-in-one anti-HIV once-daily pill Stribild has been given the green light by the FDA for adults who have not …
New Quad HIV pill on track for FDA approval
May 14, 2012Research and Development, Sales and Marketing BMS, Compera, FDA, Gilead, HIV, The Quad
Gilead Sciences’ four-in-one HIV pill has been given the thumbs up by an FDA advisory group. The US regulator is …
Setback for Gilead hep C candidate
February 20, 2012Research and Development, Sales and Marketing ELECTRON, GS-7977, Gilead, Pharmasset
Gilead’s investigational hepatitis C drug has been dealt a blow after patients suffer relapses in a mid-stage trial. In the …
Gilead aims for hep C lead with Pharmasset acquisition
November 22, 2011Research and Development Gilead, HCV, Pharmasset, Victrelis, hepatitis C
Gilead Sciences is to buy Pharmasset for $11 billion in a bid to become a leader in hepatitis C treatment.The …
Boehringer signs away HIV rights to focus on hep C
October 7, 2011Research and Development Boehringer, Gilead, HIV, hepatitis C
Boehringer Ingelheim has signed a deal giving Gilead Sciences exclusive worldwide rights to a major part of its HIV portfolio. …
Gilead buys manufacturing plant from Genentech
August 9, 2011Manufacturing and Production Genentech, Gilead, biologics
Roche unit Genentech has agreed to sell a clinical manufacturing plant in California to Gilead Sciences. The 70,000 sq. ft. …
Gilead manufacturing under investigation by US authorities
June 14, 2011Manufacturing and Production Department of Justice, Gilead, manufacturing compliance, pharma manufacturing
Gilead Sciences is being investigated by the US authorities over the manufacturing and distribution of some of its products, and …
Latest content
NIHR chief scientific adviser visits Huddersfield health innovation campus
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
